CNBX PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0108 USD | -16.92% |
|
-5.26% | -23.94% |
Valuation
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 110.5 | 35.08 | 25.8 | 24.93 | 4.277 | 0.3526 |
| Enterprise Value (EV) 1 | 109.1 | 31.55 | 25.02 | 24.42 | 5.918 | 1.566 |
| P/E ratio | -29 x | 30.5 x | -3.44 x | -7.37 x | -1.12 x | -0.04 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11,507 x | 3,564 x | 3,605 x | - | - | 0.86 x |
| EV / Revenue | 11,362 x | 3,206 x | 3,496 x | - | - | 3.82 x |
| EV / EBITDA | -29.3 x | -10.1 x | -8.85 x | -10.3 x | -2.15 x | -2.04 x |
| EV / FCF | -70.7 x | -12.5 x | -23.9 x | -16.5 x | -11.5 x | 6.7 x |
| FCF Yield | -1.41% | -7.97% | -4.19% | -6.06% | -8.69% | 14.9% |
| Price to Book | 41.8 x | 2.38 x | 14.6 x | 14 x | -2.62 x | -0.19 x |
| Nbr of stocks (in thousands) | 1,012 | 1,121 | 1,126 | 1,222 | 1,258 | 20,861 |
| Reference price 2 | 109.2 | 31.30 | 22.92 | 20.40 | 3.400 | 0.0169 |
| Announcement Date | 11/29/18 | 11/29/19 | 11/4/20 | 11/29/21 | 11/30/22 | 11/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.009601 | 0.009843 | 0.007157 | - | - | 0.4102 |
| EBITDA 1 | -3.72 | -3.115 | -2.828 | -2.379 | -2.755 | -0.7693 |
| EBIT 1 | -3.809 | -3.304 | -3.043 | -2.6 | -2.954 | -0.9314 |
| Operating Margin | -39,670.12% | -33,563.01% | -42,524.13% | - | - | -227.07% |
| Earnings before Tax (EBT) 1 | -3.777 | 1.133 | -7.467 | -3.194 | -3.723 | -3.71 |
| Net income 1 | -3.777 | 1.133 | -7.467 | -3.194 | -3.723 | -3.71 |
| Net margin | -39,335.66% | 11,510.41% | -104,337.91% | - | - | -904.57% |
| EPS 2 | -3.765 | 1.026 | -6.660 | -2.767 | -3.045 | -0.4204 |
| Free Cash Flow 1 | -1.543 | -2.515 | -1.048 | -1.479 | -0.5141 | 0.2338 |
| FCF margin | -16,070.46% | -25,547.38% | -14,637.47% | - | - | 57.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/29/18 | 11/29/19 | 11/4/20 | 11/29/21 | 11/30/22 | 11/30/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.64 | 1.21 |
| Net Cash position 1 | 1.39 | 3.52 | 0.78 | 0.51 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.5956 x | -1.578 x |
| Free Cash Flow 1 | -1.54 | -2.51 | -1.05 | -1.48 | -0.51 | 0.23 |
| ROE (net income / shareholders' equity) | -135% | 13% | -90.5% | -179% | -4,289% | 203% |
| ROA (Net income/ Total Assets) | -69.8% | -22.5% | -21.9% | -61.3% | -94.9% | -88.9% |
| Assets 1 | 5.412 | -5.039 | 34.16 | 5.207 | 3.923 | 4.175 |
| Book Value Per Share 2 | 2.610 | 13.20 | 1.570 | 1.460 | -1.300 | -0.0900 |
| Cash Flow per Share 2 | 1.380 | 0.2400 | 0.6900 | 1.120 | 0.0900 | 0.0100 |
| Capex 1 | 0.94 | 0.22 | 0.08 | 0 | 0 | - |
| Capex / Sales | 9,815.58% | 2,203.41% | 1,058.38% | - | - | - |
| Announcement Date | 11/29/18 | 11/29/19 | 11/4/20 | 11/29/21 | 11/30/22 | 11/30/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -23.94% | 336K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CNBX Stock
- Financials CNBX Pharmaceuticals Inc.
